Clinical Trial Update: A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease. [Phase 2]

View source ↗

Summary

Phase 2 trial of intravenous ibandronate (Bondronat) in breast cancer patients with metastatic bone disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Breast Cancer

Drugs mentioned

• Bondronat (ibandronic acid)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Pain, Bone Neoplasm | Phase 2 | Status: WITHDRAWN